Blog
RSS FeedPosted by Michael Wonder on 23 Jan 2019
ICER launches international collaborative to develop new methods to guide value-based pricing of potential cures
23 January 2019 - NICE in the UK and CADTH in Canada among international agencies participating; public input on key methodological ...
Posted by Michael Wonder on 21 Jan 2019
New whitepaper identifies limitations in using ICER’s “potential budget impact” work to guide private payer budget decisions
18 January 2019 - A new whitepaper authored by Bruce Pyenson and colleagues from Milliman explains why ICER potential budget ...
Posted by Michael Wonder on 11 Jan 2019
ICER posts draft scoping document for the assessment of treatments for Duchenne muscular dystrophy
11 January 2019 - Document open to public comment until 1 February 2019. ...
Posted by Michael Wonder on 20 Dec 2018
Institute for Clinical and Economic Review provides policy recommendations for biologic treatments for uncontrolled asthma
20 December 2018 - Expert roundtable suggests that lower prices, needed to align pricing fairly with the added value for patients, ...
Posted by Michael Wonder on 03 Dec 2018
Institute for Clinical and Economic Review provides policy recommendations for extended-release treatments for opioid use disorder
3 December 2018 - CAM2038 could reach fair value-based price if launched with annual price less than $5,300. ...
Posted by Michael Wonder on 29 Nov 2018
Amgen cuts Repatha’s price by 60 percent. Will value-based pricing support value-based patient access?
28 November 2018 - Recently, Amgen announced a 60% reduction in the list price of its PCSK9 drug Repatha for patients ...
Posted by Michael Wonder on 29 Nov 2018
ICER Appoints Athelia "Tia" Tilson as Vice President of Development
29 November 2018 - ICER has appointed Athelia “Tia” Tilson as the organization’s first Vice President of Development. ...
Posted by Michael Wonder on 21 Nov 2018
ICER posts draft scoping document for the assessment of treatments for peanut allergy
20 November 2018 - Document open to public comment until 12 December 2018. ...
Posted by Michael Wonder on 16 Nov 2018
ICER issues final report on long-term prophylaxis for hereditary angioedema, provides policy recommendations to improve cost-effectiveness
15 November 2018 - Cost-effectiveness and coverage considerations hinge on the frequency and intensity of attacks. ...
Posted by Michael Wonder on 14 Nov 2018
ICER report finds biologic treatments for uncontrolled asthma would require more than a 50% price discount to reach common thresholds for cost-effectiveness
13 November 2018 - Midwest CEPAC to vote on the overall value of treatments during 29 November public meeting. ...
Posted by Michael Wonder on 06 Nov 2018
Should a drug’s value depend on the disease or population it treats? Insights from ICER’s value assessments
6 November 2018 - The ICER, a private, nonprofit organisation that evaluates the clinical and economic value of prescription drugs, ...
Posted by Michael Wonder on 31 Oct 2018
ICER posts draft scoping document for the assessment of esketamine for treatment-resistant depression
31 October 2018 - Document open to public comment until 20 November 2018 ...
Posted by Michael Wonder on 31 Oct 2018
ICER posts draft scoping document for the assessment of siponimod for the treatment of secondary progressive multiple sclerosis
31 October 2018 - Document open to public comment until 20 November 2018. ...
Posted by Michael Wonder on 30 Oct 2018
Institute for Clinical and Economic Review to publish upcoming assessment on treatments for peanut allergy
30 October 2018 - Report will be subject of CTAF meeting in June 2019; open input now being accepted until 15 ...
Posted by Michael Wonder on 26 Oct 2018
Institute for Clinical and Economic Review report finds extended-release treatments for opioid use disorder provide only marginal benefits over generic alternatives, at significantly higher prices
25 October 2018 - ICER report includes value-based annual price ranges for Probuphine, Vivitrol, and CAM2038. ...